New York, June 4, 2026, 18:02 (EDT)
- ACADIA last traded at $21.72, up 1.3%, with volume of about 1.12 million shares.
- The stock lagged a stronger biotech tape: SPDR S&P Biotech ETF rose 2.7%, while iShares Nasdaq Biotechnology ETF gained 2.3%.
- Investors are looking past the last quarter toward Phase 2 data for remlifanserin in Alzheimer’s disease psychosis, expected between August and October.
ACADIA Pharmaceuticals Inc. shares rose in late U.S. trading on Thursday, helped by a firmer biotech market as investors looked toward the company’s next clinical data event rather than a fresh company announcement.
The San Diego-based drugmaker last traded at $21.72, up 1.3%, after moving between $20.90 and $21.85 during the session. Its market value stood at about $3.75 billion.
The move matters because ACADIA is in a quieter stretch between quarterly earnings and a drug-trial readout that could reset expectations for the stock. The company has said topline results — the first summary data from a clinical trial — from a Phase 2 study of remlifanserin in Alzheimer’s disease psychosis remain on track for August to October. Phase 2 is a mid-stage human trial that tests safety and early signs of benefit.
ACADIA’s business is built around two marketed drugs. NUPLAZID was approved by the U.S. Food and Drug Administration in 2016 for hallucinations and delusions tied to Parkinson’s disease psychosis, while DAYBUE was approved in 2023 for Rett syndrome in adults and children aged 2 and older.
Chief Executive Catherine Owen Adams said last month that ACADIA had delivered a “solid first quarter,” citing $268 million in total revenue and $101 million in DAYBUE sales. She also said the company was “very encouraged” by early interest in DAYBUE STIX, a powder form of the Rett syndrome drug. Acadia Pharmaceuticals
The latest quarterly filing showed product sales of $268.1 million for the three months ended March 31, up from $244.3 million a year earlier. Net income fell to $3.6 million, or 2 cents a share, from $19.0 million, or 11 cents a share, as selling, general and administrative costs rose sharply.
That mix explains some of the stock’s narrow trading. Revenue is still growing, but spending is heavier as ACADIA backs NUPLAZID and DAYBUE and moves pipeline drugs forward. The company reaffirmed 2026 guidance for total revenue of $1.22 billion to $1.28 billion.
Competition in the central nervous system, or CNS, space was mixed. Neurocrine Biosciences, another CNS-focused drugmaker, rose 1.3%, while Axsome Therapeutics slipped 0.9%.
The broader biotech trade was stronger than ACADIA’s move. The SPDR S&P Biotech ETF gained 2.7% and the iShares Nasdaq Biotechnology ETF rose 2.3%, while the Nasdaq-heavy QQQ ETF fell 0.5%.
ACADIA also remains a catalyst stock. On the May earnings call, Adams called the remlifanserin readout the company’s “most significant near-term catalyst,” while R&D head Elizabeth Thompson said management remained confident in the August-to-October timing. The Motley Fool
But the setup is not clean. ACADIA warned in its quarterly filing that its prospects depend heavily on maintaining or raising sales of NUPLAZID and DAYBUE, and that trial results may fail to meet statistical significance — the standard used to show that a result is unlikely to be due to chance. A weak remlifanserin readout, slower DAYBUE uptake or higher commercial spending could leave the stock exposed after Thursday’s modest bounce.
